High Growth Tech Stocks in US for February 2026

As February 2026 begins, the U.S. stock market is experiencing a strong start with major indices like the Dow Jones Industrial Average and S&P 500 showing significant gains, driven by positive economic indicators such as improved factory activity and new trade deals. In this dynamic environment, high growth tech stocks stand out for their potential to capitalize on technological advancements and evolving market demands, making them an intriguing focus for investors seeking opportunities in a rapidly shifting landscape.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating Marker Therapeutics 62.86% 62.39% ★★★★★★ Palantir Technologies 26.25% 28.42% ★★★★★★ Reddit 22.05% 28.08% ★★★★★★ Procore Technologies 11.43% 60.07% ★★★★★☆ Workday 10.61% 28.20% ★★★★★☆ Sandisk 28.86% 45.57% ★★★★★★ Intapp 12.01% 100.87% ★★★★★☆ Circle Internet Group 24.19% 85.43% ★★★★★☆ Zscaler 15.85% 45.68% ★★★★★☆ Duos Technologies Group 53.76% 155.11% ★★★★★☆

Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Gyre Therapeutics

Simply Wall St Growth Rating: ★★★★★☆

Overview: Gyre Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing small-molecule drugs for treating organ fibrosis, with a market cap of approximately $710.76 million.

Operations: Gyre Therapeutics focuses on developing and commercializing small-molecule drugs targeting organ fibrosis, generating $107.27 million in revenue from its Gyre Pharmaceuticals segment.

Gyre Therapeutics, recently profitable, is navigating an exciting phase with a 21.5% annual revenue growth and a notable 36.1% forecast in earnings growth per year, outpacing the US market's average. This biotech firm has successfully transitioned its focus towards innovative drug development, as evidenced by its recent Pre-NDA meetings in China for two groundbreaking therapies, F351 and Hydronidone. These drugs target significant unmet medical needs and are poised for Priority Review, enhancing Gyre's strategic positioning within the high-stakes pharmaceutical sector. With R&D expenses strategically allocated to support these initiatives—reflecting a robust commitment to innovation—Gyre is not just growing but also shaping future treatment landscapes in fibrosis and beyond.

Delve into the full analysis health report here for a deeper understanding of Gyre Therapeutics. Assess Gyre Therapeutics' past performance with our detailed historical performance reports.GYRE Revenue and Expenses Breakdown as at Feb 2026

Allot

Simply Wall St Growth Rating: ★★★★☆☆

Story Continues

Overview: Allot Ltd. is a company that specializes in developing, selling, and marketing network intelligence and security solutions across various regions globally, with a market cap of $499.55 million.

Operations: Allot Ltd. generates revenue primarily through its optical networking equipment segment, which accounts for $98.51 million.

Allot has demonstrated a robust trajectory in the tech sector, with a notable 11.7% annual revenue growth and an impressive 40.9% expected earnings growth per year, outstripping the US market average. Recently, the company raised its full-year revenue guidance to between $100 million and $103 million, reflecting confidence in its operational efficiency and market demand. Its strategic partnership with Compax Venture to implement cybersecurity services underscores Allot's commitment to innovation and sector leadership in network security solutions. This collaboration not only enhances Allot's service offerings but also positions it strongly within the growing demand for comprehensive cyber protection, essential for modern digital operations.

Take a closer look at Allot's potential here in our health report. Learn about Allot's historical performance.ALLT Earnings and Revenue Growth as at Feb 2026

Kiniksa Pharmaceuticals International

Simply Wall St Growth Rating: ★★★★★☆

Overview: Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company that develops and commercializes novel therapies for diseases with unmet needs, focusing on cardiovascular indications worldwide, with a market cap of $3.36 billion.

Operations: Kiniksa focuses on developing and delivering therapeutic medicines, generating $597.97 million in revenue from this segment.

Kiniksa Pharmaceuticals International has recently stepped into the spotlight with strategic executive appointments and a strong presence at key industry conferences, signaling a robust operational strategy. With an annual revenue growth forecast at 15% and earnings expected to surge by 30.8% per year, Kiniksa is outpacing the US market averages significantly. These figures underscore its commitment to leveraging leadership changes and AI initiatives for sustained growth in the competitive biotech landscape. The company's focus on expanding its strategic footprint, as evidenced by recent high-profile conference presentations, complements its financial trajectory promisingly.

Click to explore a detailed breakdown of our findings in Kiniksa Pharmaceuticals International's health report. Evaluate Kiniksa Pharmaceuticals International's historical performance by accessing our past performance report.KNSA Earnings and Revenue Growth as at Feb 2026

Where To Now?

Gain an insight into the universe of 73 US High Growth Tech and AI Stocks by clicking here. Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools. Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Interested In Other Possibilities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GYREALLT and KNSA.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments